NETTER-1 Results patients with neuroendocrine tumors 18% response rate - 101967

Spotlight
Video

NETTER-1 Results patients with neuroendocrine tumors 18% response rate

Loading........
Description: Bertram Wiedenmann, MD, PhD of Charité – Universitätsmedizin Berlin​ discusses the NETTER-1 results for patients with neuroendocrine tumors received an 18% response rate. Here is more details about the trial background: Patients with advanced midgut neuroendocrine tumors who have had disease progression during first-line somatostatin analogue therapy have limited therapeutic options. This randomized, controlled trial evaluated the efficacy and safety of lutetium-177 (177Lu)–Dotatate in patients with advanced, progressive, somatostatin-receptor–positive midgut neuroendocrine tumors.
Shared By : Gastrointestinal-Cancer-Meeting
Posted on : 01/19/17
Added : 2 years ago